Paper Details

  1. Home
  2. Paper Details

EphB4 as a Novel Target for the EGFR-Independent Suppressive Effects of Osimertinib on Cell Cycle Progression in Non-Small Cell Lung Cancer.

Author: AbeJiro, AsavasupreecharTeeranut, InoueChihiro, MikiYasuhiro, NanamiyaRen, Saito-KoyamaRyoko, SasanoHironobu, SatoIkuro

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study investigated the EGFR-independent effects of osimertinib, a tyrosine kinase inhibitor, on cell proliferation. The findings suggest that osimertinib can exert significant growth inhibitory effects in EGFR-mutated NSCLC patients with a high EphB4 status.
Paper Details　
Original Abstract of the Article :
Osimertinib is the latest generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor used for patients with EGFR-mutated non-small cell lung cancer (NSCLC). We aimed to explore the novel mechanisms of osimertinib by particularly focusing on EGFR-independent effects, which have not ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8395224/

データ提供：米国国立医学図書館（NLM）

EphB4 as a Novel Target for the EGFR-Independent Suppressive Effects of Osimertinib on Cell Cycle Progression in Non-Small Cell Lung Cancer

Lung cancer is like a treacherous desert storm, spreading rapidly and wreaking havoc on the body's respiratory system. This research explores the mechanisms of osimertinib, a targeted therapy for non-small cell lung cancer (NSCLC), with a specific focus on its EGFR-independent effects. The study investigates the role of EphB4, a receptor tyrosine kinase, in osimertinib's anti-cancer activity.

Osimertinib: A Multi-faceted Treatment for Lung Cancer

The study found that osimertinib can suppress cell growth and cell cycle progression in NSCLC cells, even independently of EGFR, by regulating various cellular pathways. This is like using a multi-pronged approach to combat a desert storm, utilizing multiple strategies to control the wind and protect the oasis. The research highlights the potential of osimertinib as a more comprehensive treatment for NSCLC.

Targeting EphB4 for Lung Cancer Treatment

This study suggests that EphB4 could be a novel target for enhancing the effectiveness of osimertinib in treating NSCLC. It's a reminder that even in the unpredictable desert of cancer research, there are opportunities to discover new pathways for combating these diseases.

Dr.Camel's Conclusion

This research provides valuable insights into the multi-faceted mechanisms of osimertinib in treating NSCLC. It's like uncovering a hidden network of pathways in a desert ecosystem, allowing us to target specific points to control the storm and protect the oasis. The research emphasizes the potential of osimertinib as a comprehensive treatment for NSCLC, and it highlights the importance of investigating novel targets to improve outcomes for patients with this devastating disease.
Date :
  1. Date Completed 2021-09-14
  2. Date Revised 2022-06-03
Further Info :

Pubmed ID

34445227

DOI: Digital Object Identifier

PMC8395224

Related Literature

Article Analysis
・Effects of osimertinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.